Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prelude Therapeutics ( (PRLD) ) has issued an update.
Prelude Therapeutics reported full-year 2025 financial results on March 10, 2026, and outlined a 2026 program roadmap centered on its JAK2V617F and KAT6A programs. The company ended 2025 with $106.4 million in cash and equivalents, expects its cash runway to extend into the second quarter of 2027, and reduced its annual net loss to $99.5 million as R&D and G&A expenses declined.
The U.S. FDA cleared the IND for lead JAK2V617F inhibitor PRT12396 in early 2026, with a Phase 1 trial in high-risk polycythemia vera and myelofibrosis patients expected to start by the second quarter of 2026 under an exclusive option agreement with Incyte. Prelude also advanced its highly selective oral KAT6A degrader PRT13722 toward a planned mid-2026 IND filing and second-half 2026 Phase 1 start, while expanding its degrader payload DAC collaboration with AbCellera and progressing an early-stage, wholly owned mutated calreticulin DAC program for CALR-mutant myeloid malignancies.
The most recent analyst rating on (PRLD) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.
Spark’s Take on PRLD Stock
According to Spark, TipRanks’ AI Analyst, PRLD is a Neutral.
The score is held back primarily by weak financial performance—large ongoing losses and substantial cash burn—despite improving revenue and modest leverage. Offsetting this, recent updates (earnings call and corporate events) support the development narrative via the Incyte partnership and an FDA IND clearance, while technicals and valuation signals remain mixed/neutral given unprofitability.
To see Spark’s full report on PRLD stock, click here.
More about Prelude Therapeutics
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company focused on developing innovative targeted cancer therapies for areas of high unmet medical need. Its pipeline centers on highly selective KAT6A degraders, JAK2V617F mutant-selective inhibitors, and next-generation degrader antibody conjugates that leverage targeted protein degradation technology.
The company aims to transform treatment outcomes in myeloproliferative neoplasms and ER+ breast cancer, among other indications, while also advancing proprietary degrader payloads for use in partnered DAC programs. Prelude positions itself as a leader in precision oncology, combining small-molecule degraders and novel conjugate platforms to broaden the reach of precision medicine for cancer patients.
Average Trading Volume: 435,138
Technical Sentiment Signal: Buy
Current Market Cap: $174.9M
For an in-depth examination of PRLD stock, go to TipRanks’ Overview page.